SEC Tracker
Get the app
JBIO · XBRL financial data

Jade Biosciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (JBIO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Research and development16,88417,813*20,08021,24810,32817,575*20,02322,54722,01028,541*36,05350,065
General and administrative4,4844,253*4,5384,9177,0822,408*3,3875,2315,3916,438*7,3928,851
Total operating expenses21,36822,066*24,61826,16517,41019,983*3,38727,77827,40134,979*43,44558,916
Operating income (loss)(21,368)(22,066)*(24,618)(26,165)(17,410)(19,983)*(3,387)(27,778)(27,401)(34,979)*(43,445)(58,916)
Other income (expense)15,945*1,4321,390(10)0*(2)0(28)20*(9)(62)
Income tax expense (benefit)—year only——00*—0058*1615
Net income (loss)(19,563)(20,413)*(23,186)(24,775)(16,237)(30,112)*(2,518)(32,134)(25,175)(31,932)*(40,368)(55,765)
Earnings per share, basic USD per share(0.71)(0.74)*(0.83)(0.86)(0.56)—(0.09)(0.86)(0.48)—(0.57)(0.76)
Earnings per share, diluted USD per share(0.71)(0.74)*(0.83)(0.86)(0.56)—(0.09)(0.86)(0.48)—(0.57)(0.76)
Weighted average shares, basic thousands of shares27,64127,695*27,79628,75628,86328,907*28,98528,43139,58428,356*57,77761,051
Weighted average shares, diluted thousands of shares27,64127,695*27,79628,75628,86328,907*28,98528,43139,58428,356*57,77761,051

Balance sheet

CSV

Fiscal quarters (JBIO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents32,18023,4919,12231,06931,11533,75144,220220,94250,10688,43855,085107,250
Short-term investments103,01998,94890,21273,13357,61544,87231,990—148,799247,720256,210353,955
Prepaid and other current assets2,4041,7933,9056,5581,8751,4941,1632,0422,45512,6587,22210,046
Total current assets137,603124,232103,239110,76090,60580,11777,373222,984201,360348,816318,517471,251
Property and equipment, net3162882602321462147176170157144
Right-of-use asset713614725621259209158777740726690649
Total assets140,876127,418106,821111,69490,95980,33277,533223,968202,450349,781319,433472,113
Accounts payable3,5042,3963,3134,179908224697,5861,3502,1513,9796,579
Accrued liabilities—————4,125—8,09114,0129,41914,85214,922
Total current liabilities14,72517,63715,51817,02010,3153,8282,41721,62022,35716,53922,29231,570
Lease liability, non-current358255329206810—792747724679628
Total liabilities15,15317,96215,91717,29610,4663,8982,48722,41223,10417,26322,97132,198
Accumulated deficit(143,011)(163,424)(186,610)(211,385)(227,622)(233,052)(235,570)(117,282)(142,457)(174,389)(214,757)(270,522)
Total stockholders' equity125,723109,45690,90494,39880,49376,43475,046201,556179,346332,518296,462439,915
Total liabilities and equity140,876127,418106,821111,69490,95980,33277,533223,968202,450349,781319,433472,113
Common shares outstanding (cover page) thousands of shares27,66927,86328,80828,86828,87528,98528,98532,62746,00449,31649,36063,597

Cash flows

CSV

Fiscal quarters (JBIO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(19,563)(20,413)*(23,186)(24,775)(16,237)(30,112)*(2,518)(32,134)(25,175)(31,932)*(40,368)(55,765)
Stock-based compensation3,2373,251*4,2003,8652,0031,229*1,1853,8954,2959,396*7,40513,606
Net cash from operating activities(15,611)*(14,800)*(23,673)(20,433)*(6,802)*(15,812)*(2,381)(36,535)*(22,124)*(33,649)*(24,081)(43,656)*
Purchases of property and equipment32*64*——————57*3*——
Net cash from investing activities(13,130)*5,648*8,83318,000*0*13,129*12,850(12,986)*(148,708)*(98,162)*(8,470)(97,632)*
Proceeds from issuing common stock0*0*——0*307*——————
Net cash from financing activities20*463*47124,380*94,772*(2,772)*(700)191,308*0*170,160*(795)193,523*
Net change in cash(28,721)*(8,689)*(14,369)21,947*87,970*(18,584)*10,469141,087*(170,836)*38,332*(33,353)52,165*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Jade Biosciences107,250not reported(43,656)*63.6M10.6 quarters 10-QJun 30, 2026
Standard Biotools267,48719,385(6,161)*394.8M21.6 quarters 10-QSep 30, 2026
Aquestive Therapeutics90,3497,557(7,046)*125.7M8.4 quarters 10-QSep 30, 2026
Ocugen24,6321,951(15,739)*339.3M5.1 quarters 10-QSep 30, 2026
Siga Technologies117,58441,00215,174*71.8M— 10-QJun 30, 2026
Abeona Therapeutics56,22911,380(17,496)*57.2M8.4 quarters 10-QJun 30, 2026
Tonix Pharmaceuticals Holding176,23213,544(42,243)*17.2M4.2 quarters 10-QJun 30, 2026
Vanda Pharmaceuticals61,93369,815(28,435)*60.5M1.7 quarters 10-QSep 30, 2026
Nektar Therapeutics39,26710,131(75,770)*34.1M13.5 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.